Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Markets recoup some of the losses
Fri, 27 Nov 02:30 pm

While some buying activity was witnessed at lower levels during the previous two hours of trade, the indices, nevertheless, continued to trade well below the dotted line. Stocks from the banking and realty sectors are the biggest losers while those from consumer durables and auto sectors are seeing the least declines.

The BSE-Sensex and the NSE-Nifty are trading lower, down by around 330 points and 95 points respectively. The BSE-Midcap and BSE-Smallcap are also trading lower, down by around 2.3% and 2.9% respectively. The rupee is trading at 46.98 to the dollar.

Siemens announced its full year FY09 results (September ending quarter) yesterday. The company's sales fell by just around 4% YoY during the year, led by a fall in the segments of industry automation, power transmission and healthcare. The company's operating margins expanded to 10.6% in FY09, from 8.9% in FY08. This was on account of a fall in purchase of traded goods and lower other costs (both as percentage of sales). Its net profits grew by 17.5% YoY during the quarter, helped by the expansion in operating margins, higher other income as also extraordinary income consisting of profit from the sale of investments in Siemens Information Systems Ltd. and Siemens Information Processing Services Ltd. of Rs 1.5 bn. The board has recommended a dividend of Rs 5 per share (which works out to a dividend yield of 1%) at the current market price. The stock of Siemens is trading lower currently and is infact leading the losers amongst engineering stocks.

Pharma stocks are currently trading mixed with Ranbaxy and Cipla leading the list of gainers on the exchanges. As per a leading business daily, pharma major Sun Pharma has got a tentative approval from the US drug regulator (US FDA) for its generic product 'Strattera' which is used in the treatment of mental disorders. The regulator has approved 'Strattera atomoxetine hydrochloride' capsules, which is equivalent to drug manufacturer Eli Lilly's 'Strattera' capsules. They have annual sales of nearly US$ 500 m in the US. This is a positive for the company and will help in augmenting sales from the highly competitive US generics market. Sun Pharma is currently trading marginally lower.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Markets recoup some of the losses". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.